Voxel S.A.

Specialist medical practice activities

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2005-08-02
Share capital
10,502,600.00 PLN
Activity description

Voxel is a network of diagnostic centers specializing in radiology, nuclear medicine, and advanced technology. The company offers various imaging tests, including CT scans, MRI, PET-CT, SPECT, and fusion biopsy for prostate cancer, as well as treatments like radiosynovectomy and isotope therapy for joint conditions. Voxel has been operating since 2005 and provides online registration for diagnostic examinations.

Registered address
Wielicka 265, 30-663 Kraków, Poland
Branches
  • ul. Ogrodowa 12, 15-027 Białystok
  • ul. Partyzantów 63, 43-300 Bielsko-Biała
  • ul. Krakowska 31, 32-700 Bochnia
  • ul. Kościuszki 68, 32-800 Brzesko
  • ul. Ks. J. Bielawskiego 18, 36-200 Brzozów
Website
Opening hours
Mon–Fri, 8:00–18:00
Email
Phone
Social media
Electronic delivery address
AE:PL-23931-31079-GCEDG-25

Financials

Data for 2025 is not shown: the filed document could not be read automatically.

Stock quotes

PLN 150.80
-1.40 (-0.92%)
150.00152.00154.00150.8010:0012:0014:0016:00
Open
PLN 151.20
High
PLN 154.00
Low
PLN 148.60
Volume
9.85K
Avg. vol.
11.09K
Market cap
PLN 1.6B
P/E ratio
12.86
EPS
PLN 11.85
Shares outstanding
10.5M
52-week
PLN 146.20 – 159.60
Dividend yield
1.64%
Dividend
PLN 2.50
Ex dividend date
Sep 29, 2026
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 49.92mUSD 11.66mUSD 8.79m
Q1 2026USD 42.46mUSD 11.48mUSD 8.62m
Q4 2025USD 39.08mUSD 8.51mUSD 6.23m
Q3 2025USD 35.90mUSD 9.21mUSD 6.92m

Results for Q3 2026:Nov 26, 2026

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2022.

Top <1%
Division · Human health activities25 / 7,744
Top <1%
Voivodeship · Małopolskie187 / 46,048
Top <1%
Country · Poland2,646 / 496,474
Top <1%

Results vs industry

Revenue
This companyUSD 94.05mMedianUSD 443.53kAverageUSD 1.74m
Net profit
This companyUSD 10.23mMedianUSD 14.38kAverageUSD 127.69k
Operating costs
This companyUSD 76.51mMedianUSD 396.18kAverageUSD 1.56m
Assets
This companyUSD 104.83mMedianUSD 173.37kAverageUSD 1.01m

Offer

Websites

The sites are available in: Polish and English.

  • voxel.plVoxel S.A. - diagnostyka obrazowa i terapia
    WordPressGoogle AnalyticsGoogle Tag ManagerMeta PixelYoast SEOPolylangApache
  • twojepluca.plProgram profilaktyki raka płuc
    Meta PixelApache

Public procurement

36 tenders recorded as contractor: 7 national ($808,878) and 29 EU ($14,937,928).

SubjectAmount
Supply of medicinal products and radiopharmaceuticals
$273.7K
Supply of radioisotope materials
$164.4K
Provision of PET-CT and choline PET-CT examinations for oncological diagnoses using group I and II radiopharmaceuticals for 5 WSZKzP SPZOZ in Kraków
$268.8K

National Health Fund (NFZ) contracts

The company has been an NFZ healthcare provider since 2008. In 2026 it is performing 24 contracts with a total value of USD 68.02m. All its contracts were worth USD 485.53m in total.

NFZ contract value by year (in m USD)

Type of careNFZ branchContractsValue in 2026
Outpatient specialist careśląskie1USD 10.59m
Outpatient specialist caremałopolskie1USD 9.88m
Separately contracted healthcare servicesśląskie1USD 7.04m
Separately contracted healthcare servicesłódzkie1USD 6.50m
Outpatient specialist carepodkarpackie1USD 4.71m

NFZ waiting lists

This company's facilities run 48 NFZ waiting lists. Waiting time forecast by NFZ, as of 11.11.2026.

ServiceWaiting time
Isotope therapy3 days
Computed tomography7 days
Positron emission tomography10 days
Positron emission tomography12 days
Nuclear medicine examinations15 days

Trademarks

The company holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2009.

MarkNumberClassesStatusProtected until
voxel Z.35568010, 42, 44Protected May 11, 2029
MarkProtected until
voxel May 11, 2029

Job offers

The company lists 6 job openings on its own careers page: voxel.pl/grupa-voxel/kariera.

Position
Chief accountant Katowice
Radiology registration clerk Sosnowiec
Radiology registration clerk Kraków

Authorized Representatives

Jarosław Furdal age 60 – President of the Management Board
Grzegorz Rutkowski age 58 – Vice President of the Management Board

Manner of representation

Two members of the management board acting jointly or one member of the management board acting jointly with a commercial proxy are authorized to submit declarations of will and sign documents on behalf of the company.

Supervisory board

Martyna Liszka-Białek age 38 – Supervisory Board Member
Jakub Jan Kowalik age 48 – Supervisory Board Member
Vladimír Ježík – Supervisory Board Member
Magdalena Katarzyna Pietras age 38 – Supervisory Board Member
Wojciech Tomasz Napiórkowski age 52 – Supervisory Board Member

Beneficial owners

Voxel is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.

Subsidiaries

NameStake
100%
Voxel Inwestycje sp. z o.o.
100%
Alteris S.A.
100%

Capital group

The company is the parent company of a corporate group.

NameOwnership
Inwestycje sp z o.o.
100%
100%
63.73%

Bank accounts

Registered as a VAT taxpayer on 2005-07-01.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Jan 22, 2019Other notice
Dec 10, 2015Other notice
Apr 29, 2013Commercial Companies Code notice
Nov 30, 2012Other notice

Public aid

8 public aid cases recorded, with a total value of $2,120,126.

PurposeGross amount
Aid for research and development projects: industrial research
$914.7K
Aid for research and development projects: experimental development
$199.2K
Aid for research and development projects: experimental development
$329.8K

European Funds

4 projects co-financed from European Funds recorded, with total EU co-financing of $1,011,234.

ProjectEU co-financing
Conducting research and development work aimed at implementing a process innovation based on artificial intelligence in MRI diagnostic imaging facilities
$329.9K
Expansion of the R&D department to conduct research on new radiopharmaceuticals
$221.6K
Development work to implement an innovative technology for a new line of radiopharmaceuticals
$403.4K

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Kliniki Neuroradiochirurgii sp. z o.o.
Tomma Diagnostyka Obrazowa S.A.
Salve Medica sp. z o.o. + limited partnership
Affidea Onkoterapia sp. z o.o.
NU - Med Grupa S.A.
Wizja V sp. z o.o.
Polmed Diagnostyka sp. z o.o.
Mruk-MED I sp. z o.o.
Centrum Diagnostyki Medycznej Multi-Med S.A.
Diagnostyka Wyrobek sp. z o.o.

Change history

DateEvent
2025-09-05Switch to PKD 2025
2019-10-03PKD change
2013-07-31Share capital increase
2013-04-18Share capital increase
2013-03-15PKD change

FAQ

Last updated: 2026-07-31